$PGNX #1 Progenics (PGNX) stock soared 148% while Gilead

New Post Public Reply Private Reply Replies (0) Message Board
mick
120
$PGNX #1 Progenics (PGNX) stock soared 148% while Gilead (GILD) stock fell 24%.
https://order.investorplace.com/?sid=A6C537&en=4822379
The difference?

Progenics saw its sales jump 3,757% in the third quarter of 2016 compared to the prior year, while Gilead’s sales fell 6% in 2016.

Not to beat up on Gilead, but you can see that same battle for customers and profits at hand when comparing Tenet Healthcare Corp (THC) and Hospital Corporation of America (HCA).

Over the past 12 months, Tenet Healthcare saw its stock collapse 19% while Hospital Corporation of American saw its fortunes rise 30%.

The difference here came down to earnings growth. You see, while HCA’s earnings per share grew 46% in 2016, Tenet Healthcare’s balance sheet poses a threat to its financial future.

The result will send their stock prices south… while those with the fattest profit margins and the greatest sales and earnings growth will continue to dominate their sectors and reward their investors along the way.

That’s why the companies with the greatest market share and the fattest operating and profit margins AND the biggest medical breakthroughs will have an overwhelming advantage over those that don’t, as the President’s new health care reform works to lower consumer costs across the board.

Buy global generic drug companies with dominant market share
Why? Because they already have larger profit margins, since they don’t have any of the research and development costs that the big pharmaceutical companies have.

They simply wait for the drug patents to expire and begin producing generics AND PROFITS. This is how they can make a medication that is identical to a brand-name product, for pennies on the dollar—passing the savings on to the consumer.

Buy pharmaceutical research companies with a huge pipeline of products ready to come to market.
As Trump said repeatedly on the campaign trail, he wants the FDA to approve drugs much faster. It’s no wonder. In 2016, the FDA approved just 22 new medicines—a six-year low, according to The Hill.

“There are over 4,000 drugs awaiting approval,” candidate Trump said in an October 2016 speech, “and we especially want to speed the approval of life-saving medications.” He repeated that promise again on January 31, 2017, telling a group of pharmaceutical industry executives, “We’re forced and focused on accelerating FDA approvals. We’re gonna get the approval process much faster.”

As a result, you are going to see that approval process speed up on developing new drugs for diabetes, cardiovascular disease, obesity, and Alzheimer’s disease—not one of which was approved in 2016.

Buy medical device, medical technology, and diagnostic companies with the fattest profit margins and the greatest pricing power.

Please do so quickly.
In January, Congressman Erik Paulsen (R-MN) introduced a bill that would permanently repeal the 2.3% tax on medical devices under Obamacare. Once passed, this bill would permanently keep the tax from taking effect.

According to Congressman Paulsen, "We are already seeing new American jobs and increased investment in research and development as a result of the temporary suspension of this tax.”

It’s no wonder. The repeal of these taxes eliminates one half of the double hit these companies have taken from Obamacare. Not only were manufacturers subject to a 2.3% tax on sales, but Medicare reimbursements were reduced as well.

Together, these taxes on medical devices, diagnostic imaging, and lab equipment created a disincentive to purchase new medical innovations.

Profit Taker No. 1 $TEVA
When President Trump’s new health care plan becomes law, generic drug companies should outperform the market by a country mile. Now is the time to purchase them, as health insurance and government payers will ultimately push millions of Americans to use them.

For these reasons, Teva Pharmaceutical Industries (TEVA) will be one of the biggest profit takers of all.

It’s no wonder. With a product portfolio of more than 1,800 molecules, the company fills more than 1.5 million prescriptions a day in the U.S.—generating more than $20 billion in sales annually.

In fact, as I write this, the company not only plans to launch 1,500 generics in 2017 but also has over 338 product registrations pending FDA approval. The result will turbo-charge the company’s profits as their new products funnel billions of dollars away from the world’s biggest brands and into their own coffers.


First, the company is on track to generate 300% earnings growth in the first quarter of 2017. Second, they are the world’s largest and most competitive generic drug manufacturer. And third, no matter what the outcome of the new health care law, millions of Americans are still going to need the medicines that TEVA produces.







Scroll down for more posts ▼

Top 10 Most Recent News Articles

Thanksgiving AI Talk Needs Better Safety Questions

Updated Category News Views 108

Thanksgiving has somehow acquired a new household hazard: somebody casually pasting private information into a chatbot between football and dessert. SBS CyberSecurity’s point is sensible, and it lands because this is no longer a niche tech habit. Pew Research Center says 49% of U.S. adults use AI chatbots, up from roughly one-third in 2024. That kind of adoption curve...

Continue Reading
Ajman Forum Puts Trust at the Center of Crisis Media

Updated Category News Views 39

Rumours do not wait politely for a communications team to finish its meeting. That plain reality sat underneath Abdulla bin Mohammed bin Butti Al Hamed's keynote at Ajman Media Forum 2026, and it is a tougher point than the usual talk about reach, engagement, or flashy new technology. In a crisis, an information vacuum gets filled fast, usually by somebody with no...

Continue Reading
ACOLT Bets on Gold, Craft, and a Sci-Fi Story World

Updated Category News Views 43

A gold pendant moonlighting as a plot device is not the usual luxury pitch, and thank goodness for that. ACOLT, the Denver-based men's fine jewelry house founded by Colton Hindle, plans an international December 2026 launch of its Gold Collection alongside CHRYSON Volume 1: The Arrival, an original science-fiction comic. The actual hand-forged pieces are meant to show up...

Continue Reading
Schloss Johannisberg Leads 2026 Global Vineyard List

Updated Category News Views 179

A 1,200-year-old riesling estate just beat the world at being memorable. Schloss Johannisberg in Germany’s Rheingau has taken No. 1 in The 50 Best Vineyards 2026, moving up from No. 2 last year and also claiming Best Vineyard in Europe. For anyone watching the wine business from the outside, this is not really a story about one bottle edging out another. It is a...

Continue Reading
Implantica's U.S. Launch Arrives With Cash Still to Burn

Updated Category News Views 113

RefluxStop has finally stepped onto American soil, and that changes the conversation around Implantica in a very real way. FDA Premarket Approval arrived on August 20, then the first U.S. procedures were completed in early November at the University of Southern California. For a small medtech outfit, clearing that regulatory gate and getting actual patients treated are...

Continue Reading
Ajman Media Forum Puts Trust Ahead of AI Speed in 2026

Updated Category News Views 156

Algorithms may manufacture a flood of words, but they cannot inherit accountability. That was the sensible nerve running through Ajman Media Forum 2026, “The Signal,” inaugurated on November 19 by His Highness Sheikh Ammar bin Humaid Al Nuaimi, Crown Prince of Ajman and Chairman of the Executive Council. For all the fanfare that usually surrounds artificial...

Continue Reading
Rafay's Third Fast 500 Nod Tracks AI Cloud Buildout

Updated Category News Views 24

GPU warehouses are easy to admire and brutally hard to operate like a real business. Rafay Systems landing on Deloitte's 2026 Technology Fast 500 for a third straight year is another signal that the AI infrastructure scramble has moved well beyond simply finding chips. Somebody has to turn all that expensive compute into services customers can provision, use, measure and...

Continue Reading
Innogen's Arcera Deal Tests Its GLP-1 Global Reach

Updated Category News Views 115

A License Deal With Actual Cash Attached Drug licensing announcements can smell like expensive perfume: plenty of promise, hard to tell what is really in the bottle. This one at least arrives with a concrete number. Innogen Pharmaceuticals will receive US$38 million in upfront and near-term milestone payments from Arcera Life Sciences for Efsubaglutide Alfa, including a...

Continue Reading
FLX Opens a New Door to Pre-IPO Deal Flow for Advisors

Updated Category News Views 82

Private-market chatter has been leaking past the velvet rope for years, and advisors are sick of learning about it after a client already has a pitch deck in hand. FLX Networks is responding to that irritation by letting its eligible advisor and wealth-management members review select pre-IPO opportunities shared by other members. Announced November 19, 2026, the move is...

Continue Reading
Getac's Linux Certification Matters at the Rugged Edge

Updated Category News Views 73

Field computers rarely get applause, but they can decide whether a critical operation runs cleanly or turns into a very expensive mess. Getac’s November 19 announcement that its UX10, G140, and V120 rugged devices are certified for Red Hat Enterprise Linux is not the sort of headline that sends investors pounding the table. It is, however, the kind of plumbing work that...

Continue Reading

Top 5 Most Recently Viewed Articles

Globeleq Strengthens Leadership with Alasdair Martin's Appointment

Updated Category News Views 169

Globeleq Welcomes Alasdair Martin as Director of Private Customer Solutions Globeleq, a prominent independent power company in Africa, has appointed Alasdair Martin to the crucial role of Director of Private Customer Solutions. This appointment is a strategic move that aligns with the company's vision for growth through innovation and sustainable energy transformation in...

Continue Reading
Orthofix Medical's Q4 2026 Earnings: Unpacking The Numbers

Updated Category News Views 186

Earnings Breakdown Let's get into the nitty-gritty of Orthofix Medical's earnings for Q4 of 2026. Rollercoaster ride, anyone? They posted an earnings-per-share (EPS) of $0.24, which is a solid beat over the $0.12 consensus estimate. That's a clean 100% overcall—on paper, that's the kind of news that gets you smiling on your way to the bank. Honestly, an earnings double...

Continue Reading
bioAffinity Technologies Achieves Milestone with CyPath® Lung Test

Updated Category News Views 106

bioAffinity Technologies Celebrates Initial Success of CyPath® Lung b>bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), dedicated to advancing noninvasive cancer detection and lung disease diagnostics, has unveiled remarkable outcomes from its recent pilot marketing program for the CyPath® Lung test. Focused on enhancing patient care, the Texas beta launch has seen...

Continue Reading
Hamilton Beach Brands Reports Strong Q3 Performance for 2024

Updated Category News Views 145

Company Overview Hamilton Beach Brands Holding Company (NYSE: HBB) is an established leader in the design, marketing, and distribution of a variety of small electric household appliances and specialty products. With a portfolio that includes well-known consumer brands such as Hamilton Beach® and Proctor Silex®, the company continues its mission to enhance daily living...

Continue Reading
Melexis Expands Treasury Share Holdings with Recent Buyback

Updated Category News Views 155

Melexis Share Buy-Back Program Update Melexis is excited to share an update regarding its ongoing share buy-back program, originally announced several months ago. This initiative aims to enhance shareholder value and stabilize stock prices in today’s dynamic market environment. As part of this program, Melexis has recently engaged in notable share purchases on Euronext...

Continue Reading